Impax AM secondary placing sees BNPP AM sell 10.5% of issued share capital

Shares sold at 510p per share

clock
The placing shares represent approximately 10.5% of the company's issued share capital
Image:

The placing shares represent approximately 10.5% of the company's issued share capital

BNP Paribas Asset Management (BNPP AM) has sold 13,661,888 ordinary shares in Impax Asset Management Group at a price of 510p per share following an announcement yesterday (10 November) in relation to a proposed placing of ordinary shares.

In a statement about the results of the secondary placing in Impax Asset Management Group, it was confirmed that the placing shares represent approximately 10.5% of the company's issued share capital. Settlement of the placing is expected to occur on 13 November 2020 and following completion of the placing, BNPP AM will continue to hold 18,258,112 ordinary shares in Impax, representing approximately 14% of the issued share capital of the company. Impax AUM jumps to record £20.2bn on 'high levels of net inflows' BNPP AM said it had recently updated the arrangements under which it pr...

To continue reading this article...

Join Investment Week

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Equities

Dan Green, portfolio manager at Martin Currie

Three sectors that will benefit from the digital economy

E-commerce, the auction industry and cybersecurity

Dan Green
clock 12 August 2022 • 3 min read
Mike Preston, partner at Cleary Gottlieb

Private equity in sport: A growing opportunity

Expected to grow to $500bn

Mike Preston
clock 11 August 2022 • 4 min read
Ali H. Munawar, CEO of Pledge Therapeutics

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot